Trial Profile

Phase II Trial of Abaloparatide vs. Placebo in Post-Menopausal Women and Abaloparatide in Men Receiving Initial Spinal Fusion Surgery

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 18 Jun 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Abaloparatide (Primary)
Indications Postmenopausal osteoporosis
Focus Adverse reactions; Proof of concept; Therapeutic Use

Most Recent Events

12 Jun 2024 Number of treatment arms are increased from 2 to 3 by the addition of Experimental: Abaloparatide (Men) arm. Additionally, as Tymlos is now approved for treatment in men, the study will include 24 men aged 55 and over to be treated in an open-label design.
12 Jun 2024 Planned number of patients changed from 72 to 96.
12 Jun 2024 Planned End Date changed from 1 Oct 2024 to 1 Sep 2026.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com